TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35213415
Drug: TMB-L +
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMB-L + BRAF WT
Study: 35213415
Drug: TMB-L +
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMB-L + NRAS mut
Study: 35213415
Drug: TMB-L tumors
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMB-L tumors
Study: 34072223
Drug: One-off application
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-off application of a structured 5-step implicit process to simplify medication regimens.
Study: 34072223
Drug: One-off implicit
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-off implicit medication simplification intervention.
Study: 33035492
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 20 mg/kg
Study: 33035492
Drug: Intravenous normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous normal saline (0.09%)
Study: 34181143
Drug: 1-mg melatonin
Normalized name: melatonin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg melatonin
Study: 34181143
Drug: 4-mg melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg melatonin
Study: 34859852
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus Vitamin D supplementation
Study: 34859852
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without Vitamin D
Study: 38874618
Drug: Neither therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither therapy
Study: 32864597
Drug: Sensor-Augmented Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-Augmented Pump Therapy (SAP)
Study: 36307274
Drug: Lifestyle plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle plus medication therapy management
Study: 35587681
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen inhalation
Study: 33001381
Drug: Spatz3® adjustable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spatz3® adjustable intragastric balloon (IGB) with upward adjustment (250 mL greater volume)
Study: 33001381
Drug: Spatz3® adjustable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spatz3® adjustable intragastric balloon (IGB) with constant volume (600 mL)
Study: 32562076
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 200-mW, 6-J, continuous-wave mode for 30 seconds
Study: 35988206
Drug: Papaverine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine infusion through aortic root
Study: 32503620
Drug: Lopinavir/Ritonavir (Kaletra)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (Kaletra) + Colchicine 1.5 mg loading then 0.5 mg twice daily orally
Study: 33259999
Drug: Transvaginal high-intensity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvaginal high-intensity focused ultrasound (vHIFU) therapy
Study: 33877743
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg daily for 7 days)
Study: 33877743
Drug: Roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (300 mg daily for 7 days)
Study: 33877743
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antibiotics given)
Study: 32539288
Drug: 33% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 33% of daily TAF (25 mg)/FTC (200 mg)
Study: 32539288
Drug: 67% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 67% of daily TAF (25 mg)/FTC (200 mg)
Study: 32539288
Drug: 100% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% of daily TAF (25 mg)/FTC (200 mg)
Study: 32068049
Drug: 5% sofpironium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% sofpironium bromide gel
Study: 32068049
Drug: 10% sofpironium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sofpironium bromide gel
Study: 32068049
Drug: 15% sofpironium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% sofpironium bromide gel
Study: 32332634
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine foot bath decoction (FBD) with ordinary dressing changes
Study: 36306329
Drug: NETfacts health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: NETfacts health system (integrated model of Narrative Exposure Therapy and community-based intervention)
Study: 34930153
Drug: Astra‐Zeneca ChAdOx1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astra‐Zeneca ChAdOx1 vaccine
Study: 39325828
Drug: Pfizer BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfizer BNT162b2 vaccine
Study: 35318632
Drug: Multimedia insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimedia insulin pen-injector health education intervention
Study: 32741502
Drug: Oxytocin 40-IU
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 40-IU administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Study: 32741502
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intranasally prior to each of six weekly motivational interviewing group therapy (MIGT) sessions
Study: 34101252
Drug: Intensive nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive nutrition treatment (INT) with protein intake of 1.70 ± 0.21 g/kg/d
Study: 34101252
Drug: Standard nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard nutrition treatment (SNT) with protein intake of 1.06 ± 0.21 g/kg/d
Study: 34872511
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment
Study: 33155057
Drug: Green light-emitting
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green light-emitting diodes (GLED) for 1 to 2 hours daily for 10 weeks
Study: 36395875
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticagrelor (AT group)
Study: 36395875
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel (AC group)
Study: 36405056
Drug: Date palm
Normalized name: date palm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Date palm pollen (DPP) supplementation (300 mg per day for 35 days)
Study: 32966810
Drug: Surufatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib (300 mg, orally once per day)
Study: 33205673
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) at a fixed dose of 25 mg/m2/day
Study: 33205673
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) escalation (up to 50 or 75 mg/m2/day)
Study: 33205673
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD-MTX), asparaginase, and vincristine
Study: 32507128
Drug: Oxycodone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR tablet with naltrexone (T+)
Study: 32507128
Drug: Oxycodone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR tablet without naltrexone (T)
Study: 32507128
Drug: Oxygesic PR
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Polygesic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygesic PR tablet with naltrexone (R+)
Study: 32507128
Drug: Oxygesic PR
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Polygesic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygesic PR tablet without naltrexone (R)
Study: 616173046
Drug: Digoxin (D,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (D, 0.25 mg)
Study: 616173046
Drug: Ivabradine (I,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivabradine (I, 15 mg)
Study: 616173046
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-receiving both drugs)
Study: 32740086
Drug: Corticotropin-releasing factor
Normalized name: corticotropin-releasing factor
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing factor (CRF) 100 μg
Study: 32740086
Drug: 5-mL saline
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mL saline solution (placebo)
Study: 32682929
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin C daily for 30 days
Study: 32682929
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of NAC daily for 30 days
Study: 32682929
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin C
Study: 32682929
Drug: 1.2 g
Normalized name: Humidifier 1.2 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 g of NAC
Study: 32682929
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin C and 1.2 g of NAC
Study: 35413719
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1.2 g daily)
Study: 35906473
Drug: Inulin supplementation
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inulin supplementation (13 g of extracted inulin powder from Thai Jerusalem artichoke)
Study: 32631414
Drug: Individualized PEEP
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized PEEP (iPEEP) determined by Cstat-directed PEEP titration
Study: 38976448
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily for 8 weeks
Study: 34655014
Drug: High-volume group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume group received 3600 mL of lactated Ringer's solution (LRS) in 24 hours starting 2 hours before the ERCP.
Study: 33077680
Drug: Intravenous t-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous t-PA
Study: 32347139
Drug: Standard FEC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard FEC chemotherapy (600/60/600 mg/m2)
Study: 32347139
Drug: Chemotherapy-induced leukopenia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-induced leukopenia
Study: 35025757
Drug: 0.2% Hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Hyaluronic Acid cream
Study: 35025757
Drug: Neutral comparator
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral comparator cream (identical cream without HA)
Study: 35363058
Drug: Mindful Walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful Walking Program (MWP) - eight weekly sessions
Study: 32052516
Drug: Dapagliflozin (DAPA)
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin (DAPA) 10 mg + Saxagliptin (SAXA) 5 mg
Study: 32052516
Drug: Glimepiride (GLIM)
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride (GLIM) 1-6 mg (titrated)
Study: 35877601
Drug: Bedaquiline (TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline (TB drug)
Study: 35877601
Drug: Pretomanid (TB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretomanid (TB drug)
Study: 35877601
Drug: Dolutegravir (HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (HIV drug)
Study: 35877601
Drug: Doravirine (HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doravirine (HIV drug)
Study: 35877601
Drug: Sofosbuvir (HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (HCV drug)
Study: 35877601
Drug: Glecaprevir/pibrentasvir (HCV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (HCV drug)
Study: 35877601
Drug: TB drugs
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TB drugs (Bedaquiline and Pretomanid)
Study: 33978188
Drug: Citicoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (500 mg/d) for 12 weeks
Study: 35634651
Drug: Generic measures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic measures of discrimination (e.g., social distance scales)
Study: 34165010
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with 25OHD <20 ng/ml
Study: 34165010
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with 25OHD <10 ng/ml
Study: 34107861
Drug: Gui‐fu‐di‐huang‐wan (GFDHW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gui‐fu‐di‐huang‐wan (GFDHW) treatment and lifestyle intervention
Study: 34107861
Drug: GFDHW treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFDHW treatment and lifestyle intervention
Study: 34360425
Drug: Beta-Alanine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Alanine (6.4 g)
Study: 36205739
Drug: TAC-302 200
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC-302 200 mg twice daily for 12 weeks
Study: 34978388
Drug: Generic roxatidine
Normalized name: ROXATIDINE
DrugBank: Roxatidine acetate (DB08806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic roxatidine acetate hydrochloride (RAH) sustained-release capsule, 75 mg
Study: 34978388
Drug: Commercial capsule
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial capsule (ALTAT)
Study: 36506468
Drug: Early-start group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early-start group (aspirin 100 mg daily starting 3 days after operation)
Study: 36506468
Drug: Normal-start group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-start group (no antithrombotic therapy until 30 days after operation)
Study: 32606057
Drug: Vibration treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibration treatment with HMB supplementation
Study: 33326694
Drug: teriparatide (20 μg/day,
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Study: 33326694
Drug: combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined treatment of WJ‐MSCs (intramedullary [4 × 107 cells] injection and intravenous [2 × 108 cells] injection after 1 week) and teriparatide (20 μg/day, daily subcutaneous injection for 6 months)
Study: 33326694
Drug: combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined treatment of WJ‐MSCs and teriparatide
Study: 33766533
Drug: Postmastectomy radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiotherapy (PMRT) or supraclavicular radiation therapy (SCV RT)
Study: 32753064
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (crystalloid group)
Study: 34120363
Drug: Protease supplementation
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease supplementation at 500 g/ton in low protein diet (29% CP)
Study: 34120363
Drug: Protease supplementation
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease supplementation at 250 g/ton in normal protein diet (30% CP)
Study: 35642288
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained daily activities without special physical training)
Study: 34103345
Drug: Restarting antiplatelet
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Restarting antiplatelet therapy
Study: 34039013
Drug: Apalutamide (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide (240 mg/day) plus continuous androgen deprivation therapy (ADT)
Study: 34039013
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus continuous androgen deprivation therapy (ADT)
Study: 34620907
Drug: Anti-adhesion agent
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-adhesion agent Collabarrier
Study: 34620907
Drug: Placebo (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (no anti-adhesion agent)
Study: 34887317
Drug: Albuterol/budesonide (180/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol/budesonide (180/160 µg or 180/80 µg, two actuations of 90/80 µg or 90/40 µg)
Study: 34887317
Drug: Albuterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (180 µg, two actuations of 90 µg)
Study: 33205741
Drug: PfSPZ Vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ Vaccine (radiation-attenuated, 2.7 × 10^6 PfSPZ, three doses at 8-week intervals)
Study: 33205741
Drug: PfSPZ-CVac (infectious,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ-CVac (infectious, 1.0 × 10^5 PfSPZ, three doses at 4-week intervals)
Study: 32341595
Drug: Rapid glucocorticoid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid glucocorticoid tapering
Study: 32341595
Drug: Conventional glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucocorticoid tapering
Study: 34266323
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation treatment (control group) (n=48)
Study: 34263971
Drug: Licogliflozin 50
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licogliflozin 50 mg TID
Study: 33136923
Drug: Brexpiprazole (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (1, 2, or 3 mg)
Study: 33136923
Drug: Brexpiprazole (OLE,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole (OLE, flexible-dose 0.5-3 mg/d)
Study: 32233639
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment with small bone window hematoma removal
Study: 33357499
Drug: Benralizumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab (30 mg every 8 weeks, first three doses given 4 weeks apart)
Study: 35294812
Drug: donidalorsen (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: donidalorsen (80 mg)
Study: 33129289
Drug: Nano-Curcumin 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-Curcumin 80 mg
Study: 33568279
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid administration at induction for hemiarthroplasty
Study: 33568279
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid administration at induction for intramedullary nail fixation
Study: 36356829
Drug: Standard-dose nVNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose nVNS
Study: 36356829
Drug: High-dose nVNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nVNS
Study: 36252858
Drug: Laboratory digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory digital workflow (l‐DW)
Study: 32282525
Drug: Postpartum pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postpartum pelvic floor physical therapy (PFPT)
Study: 33380704
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional therapy + placebo)
Study: 35771353
Drug: BNT162b1 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b1 mRNA vaccine (10 µg dose)
Study: 35771353
Drug: BNT162b1 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b1 mRNA vaccine (30 µg dose)
Study: 35771353
Drug: BNT162b1 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b1 mRNA vaccine (in older participants)
Study: 35771353
Drug: BNT162b1 mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b1 mRNA vaccine
Study: 35314431
Drug: Non-antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotic treatment options
Study: 35314431
Drug: Postponing antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postponing antibiotic treatment by up to 3 days
Study: 34597318
Drug: Soft occlusive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft occlusive splint therapy (OST)
Study: 36221988
Drug: Increased fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased fluid consumption (≥2.2 L total beverage intake, with 1.9 L being water)
Study: 34073918
Drug: BoNT‐A injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A injection (time between stroke onset and injection ≤90 days)
Study: 34933568
Drug: REL-1017 25
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 25 mg/day
Study: 34933568
Drug: REL-1017 50
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: REL-1017 50 mg/day
Study: 33714847
Drug: Nelotanserin 80
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelotanserin 80 mg
Study: 33278897
Drug: Thermal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal therapy + exercises
Study: 33482631
Drug: Taking ≥8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking ≥8 medications
Study: 33482631
Drug: Cutoff of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutoff of 5 medications
Study: 35762448
Drug: Cloti‐Xa™ (40 mg/0.4 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloti‐Xa™ (40 mg/0.4 ml)